SAURABH SAHA
CIK 1861926 · Chief Executive Officer · last filed 2026-05-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$325.8K
Companies
2
Total Filings
67
Lifetime Open-Market Net
-$14.63M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CLVT | Director | 170,601 | $1.91 | $325.8K | $135.0K | 6 | 2026-05-15 |
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief Executive Officer | 259,017 | $40.50 | $10.49M | -$14.76M | 34 | 2025-07-21 |
Recent Filings · Page 2 of 7
67 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-22 | — | Notice (144) | −40,344 | -$501.5K | EDGAR |
| 2025-04-22 | Centessa Pharmaceuticals plc (CNTA) Delisted | Sell (S) | −55,000 | -$681.6K | EDGAR |
| 2025-04-21 | — | Notice (144) | −14,656 | -$178.9K | EDGAR |
| 2025-03-21 | Centessa Pharmaceuticals plc (CNTA) Delisted | Sell (S) | −55,000 | -$918.1K | EDGAR |
| 2025-03-20 | — | Notice (144) | −55,000 | -$899.2K | EDGAR |
| 2025-03-05 | CLVT | Buy (P) | +58,275 | $254.1K | EDGAR |
| 2025-02-20 | — | Notice (144) | −55,000 | -$874.5K | EDGAR |
| 2025-02-20 | Centessa Pharmaceuticals plc (CNTA) Delisted | Sell (S) | −55,000 | -$876.1K | EDGAR |
| 2025-02-04 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | −43,381 | -$734.0K | EDGAR |
| 2025-01-22 | Centessa Pharmaceuticals plc (CNTA) Delisted | Sell (S) | −55,000 | -$867.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.